| Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. | |
| | |
MedLine Citation:
|
PMID: 12867067 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PS-341, a potent and selective proteasome inhibitor, is the prototype for a new class of therapeutics that targets the ubiquitin-proteasome pathway. It is active as a single agent and potentiates chemotherapy and radiation in pre-clinical models. Early phase clinical studies have demonstrated tolerability and activity in multiple myeloma, lymphoma, prostate cancer and lung cancer. By its mechanism of inhibiting protein degradation, PS-341 targets a wide-range of pathways that are relevant to tumor progression and therapy resistance, and can directly modulate expression of cyclins, p27(Kip1), p53, NF-kappaB, Bcl-2 and Bax. PS-341 is currently in phase I/II clinical development in lung cancer. This paper will review the pre-clinical and clinical experience with PS-341 as it relates to lung cancer. |
| | |
Authors:
|
Philip C Mack; Angela M Davies; Primo N Lara; Paul H Gumerlock; David R Gandara |
Related Documents
:
|
21185097 - Health awareness campaigns and diagnosis rates: evidence from national breast cancer aw... 21285757 - Occult carcinoma in 866 reduction mammaplasties: preserving the choice of lumpectomy. 21547517 - False positive marks on unsuspicious screening mammography with computer-aided detection. 21132457 - Genetic risk, perceived risk, and cancer worry in daughters of breast cancer patients. 10505777 - Endometrial cancer. 7827167 - Systemic adjuvant therapy for breast cancer. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Lung cancer (Amsterdam, Netherlands) Volume: 41 Suppl 1 ISSN: 0169-5002 ISO Abbreviation: Lung Cancer Publication Date: 2003 Aug |
Date Detail:
|
Created Date: 2003-07-17 Completed Date: 2003-11-18 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8800805 Medline TA: Lung Cancer Country: Ireland |
Other Details:
|
Languages: eng Pagination: S89-96 Citation Subset: IM |
Affiliation:
|
Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA. pcmack@ucdavis.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Boronic Acids
/
administration & dosage*,
pharmacology* Cell Cycle Clinical Trials as Topic Humans Lung Neoplasms / drug therapy* Protease Inhibitors / administration & dosage*, pharmacology* Pyrazines / administration & dosage*, pharmacology* Ubiquitin / physiology |
| Chemical | |
Reg. No./Substance:
|
0/Boronic Acids; 0/Protease Inhibitors; 0/Pyrazines; 0/Ubiquitin; 0/bortezomib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antisense oligonucleotides for cancer therapy-an overview.
Next Document: Genetic testing for chemotherapy in non-small cell lung cancer.